GLP-1 receptor agonists were initially developed to treat type 2 diabetes and have had a transformative effect on its therapy, and are highly effective for glycaemic control, with the added benefit of bodyweight reduction and a low risk of causing hypoglycaemia. GLP-1 receptor agonists reduce risks for major adverse cardiovascular events (eg, non-fatal myocardial infarction, stroke, and ...
Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for the management of type 2 diabetes and obesity, yet their long-term cardiovascular effects in high-risk populations continue to be actively evaluated. Given emerging evidence of both metabolic and direct cardiovascular actions, a comprehensive synthesis of cardiovascular outcome trial data is required to clarify ...
In summary, the effects of SGLT2 inhibitors and GLP-1RAs on falls in persons with type 2 diabetes were investigated by prospectively following up hospitalized elderly and nonelderly individuals ...
Glucagon-like peptide-1 (GLP-1) receptor agonists now serve as therapeutic agents for cardiovascular diseases (CVDs) beyond their original use for treating type 2 diabetes mellitus (T2DM). This review combines molecular mechanisms with clinical evidence to demonstrate how GLP-1 agonists help lower cardiovascular risk for conditions, including atherosclerosis, heart failure, stroke, and ...
bstract Background Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated significant cardiovascular (CV) benefits, particularly in patients with diabetes mellitus, but the safety and efficacy of different GLP-1 RAs across diverse populations remain insufficiently defined.
Sarcopenia is the age-related, progressive loss of skeletal muscle mass and strength. It is a primary driver of frailty, falls, loss of independence, and all-cause mortality in the elderly. When an older adult with pre-existing, age-related muscle decline uses a GLP-1 agonist without structured intervention, they risk developing sarcopenic obesity.
GLP-1 receptor agonists in type 2 diabetes management: Current perspectives. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 15, 28812892.
However, in patients without type 2 diabetes, GLP-1 agonists had no significant effect on weight loss (SMD -0.97, p = 0.12) or improvement in fibrosis (RR 1.54, p = 0.24).
